Intra-Cellular Hid Drug Issues Before FDA Probe, Suit Says
By Cara Mannion ( May 30, 2017, 1:15 PM EDT) -- A putative class of Intra-Cellular Therapies Inc. investors on Friday in New York federal court accused the biopharmaceutical company of concealing safety concerns about its new schizophrenia medication lumateperone, saying that stock prices dropped after the U.S. Food and Drug Administration questioned the drug's effect on animals....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.